Novel Therapies for Inflammatory Bowel Disease

Sands, Bruce E.

doi:10.1016/s0889-8553(05)70059-5

Cited by 31 publications

(17 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with the demonstrated suppression of T-cell cycling, E. coli Nissle 1917-CM reduced IL-2 secretion of activated PBT, inhibiting the capacity of PBT to cycle. The potent proinflammatory cytokines TNF-␣ and IFN-␥ have been demonstrated to play a crucial role in the pathogenesis of IBD (18,54). E. coli Nissle 1917-CM profoundly reduced the secretion of these cytokines, indicating that E. coli Nissle 1917-CM has immunomodulatory capacities beyond the inhibition of cell cycling.…”

Section: Discussionmentioning

confidence: 99%

Escherichia coliNissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Escherichia coliNissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling

et al. 2005

View full text Add to dashboard Cite

“…• Interleukin 10: this cytokine has been shown to be well tolerated, and one study showed success in the treatment of patients with steroidrefractory CD [57]. • Interleukin 11: this human recombinant interleukin also has been shown to have efficacy in the treatment of active CD.…”

Section: Anti-inflammatory Cytokinesmentioning

confidence: 99%

Inflammatory bowel disease after age 60

Greenwald

Brandt

2003

Curr Treat Options Gastro

View full text Add to dashboard Cite

New-onset idiopathic inflammatory bowel disease (IBD) is not uncommon among the elderly, although more common are colonic infection, ischemia, or neoplasia, all of which may mimic IBD. Although the clinical presentation of IBD in the elderly often resembles that of younger subjects, atypical manifestations are common and may lead to difficulty in diagnosis. Much progress has been made in both medical and surgical therapy for IBD, but such therapy poses additional challenges in the elderly, who are more likely to experience adverse effects of medications or complications of surgery. The elderly generally have a favorable outcome to both medical and surgical therapy for IBD. Although concern about possible untoward effects of therapy is warranted, treatment should not be withheld because of fear of complications.

show abstract

“…The potential role of epithelial growth factors such as human growth hormone and keratinocyte growth factor in the treatment of steroid-resistant Crohn's disease is currently being examined in clinical trials [24]. Therapeutic agents affecting adhesion molecules, neuropeptides, and anti-inflammatory nuclear transcription factors, including peroxisome proliferator activating receptorgamma, also have been evaluated in steroid-resistant colitis with mixed clinical results [18,25].…”

Section: Opinion Statementmentioning

confidence: 99%

Refractory inflammatory bowel disease

Judge

Lichtenstein

2001

Curr Treat Options Gastro

View full text Add to dashboard Cite

Therapeutic options for refractory colonic inflammation in patients with ulcerative colitis or Crohn's disease have recently been augmented by the introduction of biologic therapies. Intravenous corticosteroids and cyclosporin A remain the standard therapies for severe ulcerative colitis. Monoclonal antibodies directed at tumor necrosis factor alfa (TNF-alpha) have proven to be most efficacious in patients with severe or refractory Crohn's disease. Immunomodulatory therapy with azathioprine, 6-mercaptopurine, or methotrexate has demonstrated efficacy for maintenance of remission in patients with refractory ulcerative colitis or Crohn's disease. The use of experimental biologic agents may be considered for those patients who fail to respond to or remain dependent on corticosteroids. Surgical intervention is indicated for patients with severe colitis who fail to respond to medical therapy or develop life-threatening complications such as perforation or toxic megacolon.

show abstract

Novel Therapies for Inflammatory Bowel Disease

Cited by 31 publications

References 167 publications

Escherichia coliNissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling

Escherichia coliNissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling

Inflammatory bowel disease after age 60

Refractory inflammatory bowel disease

Contact Info

Product

Resources

About